This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.
Last Updated: 11/19/2026
Milvexian is an oral investigational factor XIa inhibitor being studied for the prevention of major thrombotic conditions in a worldwide collaboration program between Bristol Myers Squibb and Johnson & Johnson. Milvexian is not currently approved for any use.
To read more about how Johnson & Johnson processes personal data, please visit https://innovativemedicine.jnj.com, select your country or region (in the upper right corner), and then click on Privacy Policy.
To read more about how Bristol Myers Squibb processes personal data, please visit https://www.bms.com, select your country (in the upper right corner), and then click on Privacy Policy.
| Phase | Trial | Description | Status | |
|---|---|---|---|---|
| Phase 3 | Librexia AF NCT05757869 | N=20,000 Aged ≥18 years | Ongoing | |
| Librexia ACS NCT05754957 | N=16,000 | Multicenter, randomized, double-blind, placebocontrolled, parallel-group, eventdriven study evaluating the efficacy and safety of milvexian 25 mg BID in participants after a recent (within 7 days) ACS2 | Discontinued | |
| Librexia STROKE NCT05702034 | N=15,000 Aged ≥40 years | Multicenter, randomized, double-blind, placebocontrolled, parallel-group study evaluating the efficacy and safety of milvexian 25 mg BID for the prevention of recurrent ischemic stroke after an AIS or high-risk TIA4 | Ongoing | |
| Phase 2 | AXIOMATIC-TKR NCT03891524 | N=1242 Aged ≥50 years | Multicenter, open-label, randomized, drug-dose blind study evaluating the efficacy and safety of milvexian vs SC enoxaparin in participants undergoing elective TKR surgery5 | Completed |
| AXIOMATIC-SSP NCT03766581 | N=2366 Aged ≥40 years | Multicenter, randomized, double-blind, placebocontrolled, dose-ranging study of milvexian for the prevention of new ischemic stroke or new covert brain infarction in participants receiving aspirin and clopidogrel following AIS or TIA7 | Completed | |
| Phase 1/2 | A study to evaluate safety of single doses of BMS986177 in patients with ESRD treated with hemodialysis NCT03000673 | N=32 Aged 1875 years | Open-label, randomized, crossover study assessing the safety and tolerability of single oral doses of milvexian in participants with ESRD treated with chronic hemodialysis9 | Completed |
| Phase 1 | Safety and tolerability study of BMS-986177 in healthy subjects NCT02608970 | N=104 Aged 18- 55 years | Two-part, randomized, double-blind, placebocontrolled, sequential SAD and MAD study evaluating the safety, tolerability, and PK of single and multiple doses of milvexian in healthy participants10 | Completed |
| Evaluate the pharmacokinetics of BMS-986177 from 2 formulations in healthy participants NCT03362437 | N=12 Aged 1855 years | Open-label, randomized study evaluating the PK of milvexian from 2 formulations (capsule and suspension) in healthy participants12 | Completed | |
| A study of JNJ70033093 (milvexian) in healthy adult participants NCT04844424 | N=115 Aged 1855 years | Open-label, randomized, crossover study assessing the relative oral bioavailability, PK, and food effect after single-dose or multipledose administration of milvexian in healthy participants using tablet, capsule, and dispersed tablet formulations14 | Completed | |
| A study of JNJ70033093 in healthy participants NCT04448964 | N=24 Aged 18-55 years | Open-label, randomized, 3-way crossover and 2-way crossover study evaluating the relative bioavailability and the food effect of an oral tablet formulation relative to a capsule formulation of milvexian in healthy participants15 | Completed | |
| A study of JNJ70033093 (BMS986177) in healthy adult participants NCT04223349 | N=66 Aged 1855 years | Open-label, single-dose crossover, double-blind, multiple-dose, parallel-group study characterizing the PK, safety, and tolerability and PD of milvexian in healthy adult participants16 | Completed | |
| A study of milvexian using an IV microtracer with additional formulation and food effect comparison in healthy participants NCT04965389 | N=17 Aged 1865 years | Open-label, randomized, crossover study assessing the absolute oral bioavailability of milvexian using a 14C-microtracer and oral solution in healthy participants with additional food effect comparison of a spray-dried dispersion formulation of milvexian in capsules17 | Completed | |
| A study to evaluate the safety and pharmacokinetics of BMS-986177 in participants with ESRD on chronic stable hemodialysis treatment NCT02902679 | N=6 Aged ≥18 years | Open-label study evaluating the safety and PK of milvexian in participants with ESRD on chronic stable hemodialysis treatment18 | Completed | |
| Evaluate pharmacokinetics and safety of BMS986177 in participants with normal renal function and with moderate or severe renal impairment NCT03196206 | N=24 Aged 1870 years | Open-label, parallel-group study evaluating the PK, safety, and tolerability of a single dose of milvexian in participants with normal renal function and with moderate or severe renal impairment19 | Completed | |
| Single-dose pharmacokinetics of BMS-986177 in participants with hepatic impairment compared to healthy participants NCT02982707 | N=26 Aged 1870 years | Open-label, parallel-group, non-randomized study evaluating the PK, safety, and tolerability of a single oral dose of milvexian 60 mg in participants with normal hepatic function (n=9), mild hepatic impairment (Child-Pugh class A; n=9), and moderate hepatic impairment (ChildPugh class B; n=8)21 | Completed | |
| Pharmacokinetic and metabolism of [14C] BMS-986177 in healthy male participants NCT03939702 | N=9 Aged 1850 years | Open-label, non-randomized study assessing the ADME of [14C] milvexian in healthy male participants23 | Completed | |
| To evaluate the safety and pharmacokinetics of BMS-986177 in healthy Japanese participants NCT03224260 | N=33 Aged 1855 years | Randomized, double-blind, placebo-controlled, MAD study assessing the safety and tolerability of milvexian in healthy Japanese participants25 | Completed | |
| A study of JNJ70033093 (BMS986177) in healthy Chinese adult participants Phase 1 NCT04569695 | N=40 Aged 1855 years | Randomized, open-label, parallel-group, single and multiple-dose study characterizing the PK, PD, and safety and tolerability of milvexian in healthy Chinese participants27 | Completed | |
| A study to evaluate the effect of coadministration of itraconazole or diltiazem on the pharmacokinetics of BMS-986177 in healthy subjects NCT02807909 | N=28 Aged 1855 years | Open-label, non-randomized trial evaluating the effects of itraconazole and diltiazem on the PK and PD of milvexian in healthy participants28 | Completed | |
| A study to evaluate the effect of rifampin on the single-dose pharmacokinetics of BMS-986177 in healthy subjects NCT02959060 | N=16 Aged 1855 years | Open-label, non-randomized, single-sequence study evaluating the effect of rifampin on the PK and PD of milvexian in normal healthy participants30 | Completed | |
| An investigational study to assess the effect of BMS-986177 on aspirin in healthy participants NCT03341390 | N=20 Aged 1855 years | Double-blind, randomized, placebo-controlled, parallel-group study evaluating the effect of coadministration of multiple doses of milvexian on aspirin in healthy participants32 | Completed | |
| A study to assess administration of an oral anti-thrombotic with antiplatelet therapy in healthy subjects NCT03698513 | N=113 Aged 1855 years | Randomized, crossover study evaluating the safety, tolerability, PK, and PD of milvexian with single and dual antiplatelet therapy (aspirin and clopidogrel) in healthy participants33 | Completed | |
| A study of JNJ70033093 and digoxin in healthy participants NCT04206488 | N=30 Aged 1855 years | Single-center, open-label, fixed-sequence study assessing the 2-way drug-drug interaction between milvexian and digoxin in healthy participants36 | Completed | |
| A study evaluating drug-drug interaction between milvexian and atorvastatin in healthy participants Phase 1 NCT04388501 | N=23 Aged 1855 years | Single-center, open-label, randomized, 3way crossover study assessing drug-drug interaction between milvexian and atorvastatin in healthy participants37 | Completed | |
| A study to assess the reversal of the anticoagulant effects of milvexian by 4FPCC) (part 1) and rFVIIa (part 2) in healthy participants NCT04543383 | N=46 Aged 1854 years | Two-part, open-label, randomized, placebocontrolled, crossover study evaluating the reversal of the anticoagulant effects of milvexian by 4F-PCC and rFVIIa in healthy participants38 | Ongoing | |
| A study of milvexian in healthy adult females NCT05706753 | N=20 Aged 1855 years | Open-label, non-randomized study assessing the effects of milvexian BID administration on the PK of single doses of midazolam, ethinylestradiol, and drospirenone in healthy adult female participants39 | Ongoing | |
| Abbreviations: 4F-PCC, 4-factor prothrombin complex concentrate; ACS, acute coronary syndrome; ADME, absorption, distribution, metabolism, and excretion; AIS, acute ischemic stroke; AF, atrial fibrillation; BID, twice daily; ESRD, end-stage renal disease; IV, intravenous; MAD, multiple ascending dose; PD, pharmacodynamics; PK, pharmacokinetics; rFVIIa, recombinant human factor VIIa; SAD, single ascending dose; SC, subcutaneous; TIA, transient ischemic attack; TKR, total knee replacement. | ||||
A literature search of MEDLINE®
| 1 | Janssen Research & Development, LLC. A study of milvexian versus apixaban in participants with atrial fibrillation (LIBREXIA-AF). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [ |
| 2 | |
| 3 | |
| 4 | |
| 5 | |
| 6 | |
| 7 | |
| 8 | |
| 9 | |
| 10 | |
| 11 | |
| 12 | |
| 13 | |
| 14 | |
| 15 | |
| 16 | |
| 17 | |
| 18 | |
| 19 | |
| 20 | |
| 21 | |
| 22 | |
| 23 | |
| 24 | |
| 25 | |
| 26 | |
| 27 | |
| 28 | |
| 29 | |
| 30 | |
| 31 | |
| 32 | |
| 33 | |
| 34 | |
| 35 | |
| 36 | |
| 37 | |
| 38 | |
| 39 | Janssen Pharmaceutica N.V., Belgium. A study of milvexian in healthy adult females. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2026 February 04]. Available from: https://clinicaltrials.gov/ct2/show/NCT05706753 NLM Identifier: NCT05706753. |
Would you like to clear and leave your conversation? Message history will be lost.